HealthStream Announces Third Quarter 2021 Results
HealthStream (Nasdaq: HSTM) reported third-quarter 2021 revenues of $64.1 million, a 5% increase from $60.9 million in Q3 2020, despite a $9.2 million decline in legacy resuscitation revenues. Operating income dropped 43% to $1.8 million, while net income also decreased 43% to $1.5 million, with EPS at $0.05, down from $0.08. Adjusted EBITDA rose 12% to $12.5 million. The company updated its 2021 guidance, projecting consolidated revenues between $255.5 - $257.5 million and adjusted EBITDA of $51.0 - $53.0 million. Cash and equivalents were reported at $60.6 million.
- Revenues increased by 5% to $64.1 million in Q3 2021 compared to Q3 2020.
- Adjusted EBITDA rose 12% to $12.5 million year-over-year.
- Operating income declined by 43% to $1.8 million in Q3 2021.
- Net income dropped by 43% to $1.5 million in Q3 2021.
- EPS decreased to $0.05 from $0.08 year-over-year.
-
Revenues of
in the third quarter of 2021, up$64.1 million 5% from in the third quarter of 2020, more than offsetting a$60.9 million decline in legacy resuscitation revenues.$9.2 million -
Operating income of
in the third quarter of 2021, down$1.8 million 43% from in the third quarter of 2020.$3.1 million -
Net income of
in the third quarter of 2021, down$1.5 million 43% from in the third quarter of 2020.$2.6 million -
Earnings per share (EPS) of
per share (diluted) in the third quarter of 2021 compared to$0.05 per share (diluted) in the third quarter of 2020.$0.08 -
Adjusted EBITDA1 of
in the third quarter of 2021, up$12.5 million 12% from in the third quarter of 2020.$11.2 million
Financial Results:
Third Quarter 2021 Compared to Third Quarter 2020
Revenues for the third quarter of 2021 increased by
Revenues from our Workforce Solutions segment were
Revenues from our Provider Solutions segment were
Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue as part of “fair value” accounting. During the third quarter of 2021,
1 Adjusted EBITDA is a nonGAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release. |
Operating income was
Net income was
Adjusted EBITDA was
At
Year-to-Date 2021 Compared to Year-to-Date 2020
For the first nine months of 2021, revenues were
Other Business Updates
At
Financial Outlook for 2021
The Company is updating its guidance for 2021 for the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2021, see the table included on page nine of this release.
|
|
Full Year 2021 Guidance |
||||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
Workforce Solutions |
|
$ |
205.0 |
|
- |
|
$ |
206.5 |
|
million |
Provider Solutions |
|
|
50.5 |
|
- |
|
|
51.0 |
|
million |
Consolidated |
|
$ |
255.5 |
|
- |
|
$ |
257.5 |
|
million |
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA1 |
|
$ |
51.0 |
|
- |
|
$ |
53.0 |
|
million |
|
|
|
|
|
|
|
|
|
|
|
Capital Expenditures |
|
$ |
25.0 |
|
- |
|
$ |
26.0 |
|
million |
1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release. |
The Company’s guidance for 2021 as set forth above reflects the Company’s assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of
The Company’s financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines continue to be successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.
Commenting on third quarter 2021 results,
A conference call with
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance. In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, the de-recognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021, and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. In addition, beginning in 2021, executive bonuses are based on the achievement of adjusted EBITDA targets.
As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two-year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two-year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company’s results of operations between periods.
Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.
This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.
About
|
||||||||||||||||
Condensed Consolidated Statements of Income |
||||||||||||||||
(In thousands, except per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
|
September 30, 2021 |
|
|
September 30, 2020 |
|
||||
Revenues, net |
|
$ |
64,091 |
|
|
$ |
60,883 |
|
|
$ |
192,374 |
|
|
$ |
183,008 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues (excluding depeciation and amortization) |
|
|
22,585 |
|
|
|
23,302 |
|
|
|
68,053 |
|
|
|
66,596 |
|
Product development |
|
|
10,344 |
|
|
|
8,192 |
|
|
|
30,205 |
|
|
|
23,491 |
|
Sales and marketing |
|
|
10,232 |
|
|
|
8,863 |
|
|
|
28,713 |
|
|
|
26,286 |
|
Other general and administrative expenses |
|
|
10,004 |
|
|
|
9,986 |
|
|
|
29,445 |
|
|
|
29,949 |
|
Depreciation and amortization |
|
|
9,141 |
|
|
|
7,406 |
|
|
|
27,443 |
|
|
|
22,005 |
|
Total operating costs and expenses |
|
|
62,306 |
|
|
|
57,749 |
|
|
|
183,859 |
|
|
|
168,327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
1,785 |
|
|
|
3,134 |
|
|
|
8,515 |
|
|
|
14,681 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (loss) income, net |
|
|
(99 |
) |
|
|
100 |
|
|
|
(250 |
) |
|
|
2,006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
1,686 |
|
|
|
3,234 |
|
|
|
8,265 |
|
|
|
16,687 |
|
Income tax provision |
|
|
186 |
|
|
|
600 |
|
|
|
2,033 |
|
|
|
3,519 |
|
Net income |
|
$ |
1,500 |
|
|
$ |
2,634 |
|
|
$ |
6,232 |
|
|
$ |
13,168 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.05 |
|
|
$ |
0.08 |
|
|
$ |
0.20 |
|
|
$ |
0.41 |
|
Diluted |
|
$ |
0.05 |
|
|
$ |
0.08 |
|
|
$ |
0.20 |
|
|
$ |
0.41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
31,558 |
|
|
|
31,955 |
|
|
|
31,538 |
|
|
|
32,095 |
|
Diluted |
|
|
31,684 |
|
|
|
31,981 |
|
|
|
31,609 |
|
|
|
32,121 |
|
|
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
|
|
|
|
|
||
|
|
2021 |
|
|
2020 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
55,459 |
|
|
$ |
36,566 |
|
Marketable securities |
|
|
5,095 |
|
|
|
9,928 |
|
Accounts and unbilled receivables, net |
|
|
30,745 |
|
|
|
46,100 |
|
Prepaid and other current assets |
|
|
20,957 |
|
|
|
22,131 |
|
Total current assets |
|
|
112,256 |
|
|
|
114,725 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
31,250 |
|
|
|
26,631 |
|
Property and equipment, net |
|
|
18,333 |
|
|
|
22,218 |
|
Operating lease right of use assets, net |
|
|
25,869 |
|
|
|
28,081 |
|
|
|
|
271,459 |
|
|
|
279,155 |
|
Deferred tax assets |
|
|
974 |
|
|
|
974 |
|
Deferred commissions |
|
|
22,860 |
|
|
|
19,907 |
|
Other assets |
|
|
11,713 |
|
|
|
8,622 |
|
Total assets |
|
$ |
494,714 |
|
|
$ |
500,313 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
27,373 |
|
|
$ |
38,266 |
|
Deferred revenue |
|
|
74,577 |
|
|
|
81,176 |
|
Total current liabilities |
|
|
101,950 |
|
|
|
119,442 |
|
Deferred tax liabilities |
|
|
18,205 |
|
|
|
14,523 |
|
Deferred revenue, non-current |
|
|
1,915 |
|
|
|
1,603 |
|
Operating lease liability, noncurrent |
|
|
26,852 |
|
|
|
28,479 |
|
Other long-term liabilities |
|
|
3,594 |
|
|
|
2,204 |
|
Total liabilities |
|
|
152,516 |
|
|
|
166,251 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
273,573 |
|
|
|
271,784 |
|
Accumulated other comprehensive income |
|
|
115 |
|
|
|
1 |
|
Retained earnings |
|
|
68,510 |
|
|
|
62,277 |
|
Total shareholders’ equity |
|
|
342,198 |
|
|
|
334,062 |
|
Total liabilities and shareholders' equity |
|
$ |
494,714 |
|
|
$ |
500,313 |
|
|
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Nine Months Ended |
|
|||||
|
|
|
|
|
|
|
||
|
|
2021 |
|
|
2020 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
6,232 |
|
|
$ |
13,168 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
27,443 |
|
|
|
22,005 |
|
Stock based compensation |
|
|
2,260 |
|
|
|
1,665 |
|
Amortization of deferred commissions |
|
|
6,900 |
|
|
|
6,555 |
|
Deferred income taxes |
|
|
2,066 |
|
|
|
2,330 |
|
Provision for doubtful accounts |
|
|
99 |
|
|
|
160 |
|
Loss on equity method investments |
|
|
258 |
|
|
|
8 |
|
Non-cash paid time off expense |
|
|
(1,011 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
(3,440 |
) |
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
(1,181 |
) |
Other |
|
|
132 |
|
|
|
321 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
13,907 |
|
|
|
(9 |
) |
Prepaid and other assets |
|
|
(8,959 |
) |
|
|
(4,019 |
) |
Accounts payable, accrued and other liabilities |
|
|
(6,668 |
) |
|
|
(3,668 |
) |
Deferred revenue |
|
|
(6,223 |
) |
|
|
(3,142 |
) |
Net cash provided by operating activities |
|
|
36,436 |
|
|
|
30,753 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(731 |
) |
|
|
(21,449 |
) |
Changes in marketable securities |
|
|
4,708 |
|
|
|
(1,656 |
) |
Payments to acquire non-marketable equity investments |
|
|
— |
|
|
|
(1,257 |
) |
Payments to acquire equity method investments |
|
|
(1,750 |
) |
|
|
— |
|
Purchases of property and equipment |
|
|
(2,602 |
) |
|
|
(1,734 |
) |
Payments associated with capitalized software development |
|
|
(16,577 |
) |
|
|
(12,366 |
) |
Net cash used in investing activities |
|
|
(16,952 |
) |
|
|
(38,462 |
) |
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Taxes paid related to net settlement of equity awards |
|
|
(471 |
) |
|
|
(429 |
) |
Repurchases of common stock |
|
|
— |
|
|
|
(16,352 |
) |
Payment of cash dividends |
|
|
(19 |
) |
|
|
(40 |
) |
Net cash used in financing activities |
|
|
(490 |
) |
|
|
(16,821 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(101 |
) |
|
|
(1 |
) |
Net increase (decrease) in cash and cash equivalents |
|
|
18,893 |
|
|
|
(24,531 |
) |
Cash and cash equivalents at beginning of period |
|
|
36,566 |
|
|
|
131,538 |
|
Cash and cash equivalents at end of period |
|
$ |
55,459 |
|
|
$ |
107,007 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) |
||||||||||||||||
(In thousands) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
GAAP net income |
|
$ |
1,500 |
|
|
$ |
2,634 |
|
|
$ |
6,232 |
|
|
$ |
13,168 |
|
Deferred revenue write-down |
|
|
805 |
|
|
|
75 |
|
|
|
3,657 |
|
|
|
355 |
|
Interest income |
|
|
(24 |
) |
|
|
(88 |
) |
|
|
(64 |
) |
|
|
(919 |
) |
Interest expense |
|
|
33 |
|
|
|
26 |
|
|
|
99 |
|
|
|
76 |
|
Income tax provision |
|
|
186 |
|
|
|
600 |
|
|
|
2,033 |
|
|
|
3,519 |
|
Stock based compensation expense |
|
|
861 |
|
|
|
557 |
|
|
|
2,260 |
|
|
|
1,665 |
|
Depreciation and amortization |
|
|
9,141 |
|
|
|
7,406 |
|
|
|
27,443 |
|
|
|
22,005 |
|
Non-cash paid time off expense |
|
|
— |
|
|
|
— |
|
|
|
(1,011 |
) |
|
|
— |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,181 |
) |
Non-cash royalty expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,440 |
) |
Adjusted EBITDA |
|
$ |
12,502 |
|
|
$ |
11,210 |
|
|
$ |
40,649 |
|
|
$ |
35,248 |
|
(1) Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release. |
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||
Financial Outlook for 2021 |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Low |
|
|
High |
|
||
Net income |
|
$ |
6,300 |
|
|
$ |
7,500 |
|
Deferred revenue write-down |
|
|
4,000 |
|
|
|
4,000 |
|
Interest income |
|
|
(100 |
) |
|
|
(100 |
) |
Interest expense |
|
|
100 |
|
|
|
100 |
|
Income tax provision |
|
|
2,100 |
|
|
|
2,600 |
|
Stock based compensation expense |
|
|
3,000 |
|
|
|
3,000 |
|
Depreciation and amortization |
|
|
36,600 |
|
|
|
36,900 |
|
Non-cash paid time off expense |
|
|
(1,000 |
) |
|
|
(1,000 |
) |
Adjusted EBITDA |
|
$ |
51,000 |
|
|
$ |
53,000 |
|
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005709/en/
Chief Financial Officer
(615) 301-3182
ir@healthstream.com
Media:
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com
Source:
FAQ
What were HealthStream's earnings for Q3 2021?
How did HealthStream's revenues perform in Q3 2021?
What is HealthStream's adjusted EBITDA for Q3 2021?
What is HealthStream's 2021 revenue guidance?